Fulgent Genetics (FLGT) to Post Q4 Earnings: What's in Store?

Published on February 21, 2022

In terms of COVID-19 NGS revenues, Fulgent Genetics (FLGT) is expected to have witnessed a rise in testing volume on increased demand through the Q4 months.

Continue reading on website
Other news

NextGen (NXGN)-Verato Tie Up to Improve Patient Insights

February 21, 2022
NextGen (NXGN) expects to deliver better insights into patient health history with its latest collaboration with Verato.

What's in the Cards for Bausch Health (BHC) Q4 Earnings?

February 21, 2022
An update on the IPO of Bausch+Lomb and regular top-line and bottom-line numbers will grab investors' attention when BHC reports Q4 results.